Beyond Prevention: Repairing Tiny Brain Arteries

Cerebral small vessel disease (CSVD), a chronic condition affecting the brain's smallest arteries, impacts an estimated 5 million people in France, significantly increasing the risk of stroke and cognitive decline. Current management focuses on preventing cardiovascular risk factors, as no cure exists. However, groundbreaking research is exploring direct therapeutic interventions.

Scientists are investigating the TRIM47 protein, which plays a protective role in maintaining vascular integrity and combating oxidative stress through the NRF2 pathway. As this defense system weakens with age, it leaves brain vessels vulnerable. Researchers aim to boost this natural defense mechanism.

Two promising strategies are underway: developing molecules that target KEAP1 to enhance the TRIM47/NRF2 pathway, and repurposing existing drugs known to activate NRF2. These approaches seek to repair and protect brain microvessels at a cellular level.

This preclinical research holds the potential to offer treatments that address the root causes of CSVD, moving beyond symptom management to preserving memory, independence, and overall quality of life. While human application requires further validation, these advancements offer a hopeful future for combating age-related cognitive impairment.